What changed in this filing

/stocks — the workspaceLOADING

Item 5. Market for Registrant’s Common Equity

2024-04-01 compared with 2023-03-31 · 17 added, 16 removed, 18 unchanged (65% of the section changed)

Market for Registrant’s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity

Market for Registrant’s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities

Market Information

1 unchanged sentence

are currently listed on the Nasdaq Capital Market under the symbols “CDIO” and “CDIOW,” respectively.

the consummation of the Business Combination on October 25, 2022, Mana’s units, Common Stock, public warrants and rights were listed

on the Nasdaq Global Select Market under the symbols “MAAQU,” “MAAQ,” “MAAQW” and “MAAQR,”

respectively.

There was no public trading market for Legacy Cardio’s equity.

As of March 27, 2023, there were 91 holders

of record of our common stock and ten holders of record of our Public Warrants and Sponsor Warrants.

In addition, we have approximately

73 holders of private placement warrants, the majority of which have been registered for resale on a registration statement on Form S-1

that the SEC declared effective on January 24, 2023.

As of April 1, 2024, there were 37

holders of record of our common stock and six holders of record of our Public Warrants and Sponsor Warrants.

In addition, we have

approximately 73 holders of private placement warrants, the majority of which have been registered for resale on a registration

statement on Form S-1 that the SEC declared effective on January 24, 2023.

The number of record holders of our Common Stock

9 unchanged sentences

and other factors the Board considers relevant.

At March 27, 2022, there were 7,854,620 warrants

outstanding for the purchase of Company Common Stock.

Refer to Note7 to the consolidated financial statements included in this Annual

Report on Form 10-K for additional information relating to outstanding warrants.

As of April 1, 2024, there were

8,528,766 warrants outstanding for the purchase of Company Common Stock.

Refer to Note 10 to the consolidated financial statements

included in this Annual Report on Form 10-K for additional information relating to outstanding warrants.

Securities Authorized for Issuance Under

Equity Compensation Plans

III, Item 11, “Executive Compensation,” for information about securities authorized for

issuance under the Company’s equity compensation plan.

III, Item 11, “Executive Compensation,” for information about securities authorized

for issuance under the Company’s equity compensation plan.

Sales of Unregistered Securities

We did not sell

any equity securities that were not registered under the Securities Act during the fiscal year ended December 31, 2023 that were

not otherwise disclosed in our Quarterly Reports on Form 10-Q or our Current Reports on Form 8-K.

Issuer Purchases of Equity Securities

We do not currently have any plans under which

the Company is able to repurchase shares of our equity securities from our stockholders.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 5. Market for Registrant’s Common Equity